S
troke among atrial fibrillation (AF) patients has been shown to be associated with increased severity, functional disability, and mortality compared with patients without AF. 1 While stroke-related costs have been estimated among a general population, 2 limited data exist on the economic implications of stroke among patients with AF. In this retrospective study, we estimate the cost of ischemic stroke (IS), hemorrhagic stroke (HS), and transient ischemic attack (TIA) among patients with AF versus those without AF from a third-party payer perspective. These data will provide a baseline estimate on the economic burden of stroke to inform future cost-benefit evaluation of interventions aimed at preventing stroke in AF patients.
Methods Data Source
This study used administrative claims data from the Truven Health Analytics 
Patient Selection
We identified adult patients (≥18 years of age) with at least 1 primary inpatient diagnosis of stroke or TIA diagnosis constituted the index date. Patients could not have had a stroke or TIA diagnosis in the 12 months prior to the index stroke (ie, to ensure a "baseline period" without stroke or TIA) and were required to be continuously eligible for 12 months prior to the index stroke event.
Presence of AF was based on ≥1 inpatient or ≥2 outpatient claims (separated by <1 year) associated with an AF diagnosis (ICD-9-CM: 427.31) 7, 8 in the baseline period and up to 3 months after index stroke event to allow inclusion of patients who were identified to have AF after stroke occurrence.
Study Measures
The following baseline demographic and clinical characteristics were evaluated-age, sex, geographic region, metropolitan statistical area, year of index stroke diagnosis, type of stroke or TIA, comorbidities, use of oral anticoagulants (ie, 
0.0520
Continued warfarin, dabigatran, and rivaroxaban), inpatient and ED resource use, and duration of follow-up. Outcomes included index hospitalization length of stay (LOS), index event costs (all costs occurring throughout the timeframe of the index hospitalization or ED visit), hospitalization rates within 30 days of index event, stroke-related hospitalization rates 12 months post-index, and strokerelated costs 12 months post-index for all components of medical care. Stroke-related costs and hospitalizations were required to list a stroke/TIA ICD-9-CM code.
Costs data reflect the total gross payments to all providers associated with a given medical event. Total stroke-related costs were derived by summing all payments associated with a stroke/TIA admission (based on primary or any ICD-9-CM diagnosis code) over the 12-month follow-up period for all places of service (eg, inpatient, outpatient, emergency department, skilled nursing facility, home health care, durable medical equipment). Stroke-related laboratory and pharmacy costs (ie, the presence of select medications, including anticoagulants such as warfarin, dabigatran, and rivaroxaban, as well as antiplatelets and rate/rhythm control medications) were included in the calculation of total costs.
Follow-up analysis included those patients who were continuously enrolled for 12 months following the index event.
Statistical Analyses
We compared adjusted index event LOS and stroke-related cost between patients with and without AF using a generalized linear model with a negative binomial distribution and a log link, controlling for age, sex, geography, year of index diagnosis, selected comorbidities (based on >5% frequency), oral anticoagulant (OAC) use, and baseline hospital and ED use. Given common characteristics observed in healthcare cost data, such as a highly skewed distribution from the small percentage of patients with extremely high expense rates, the generalized linear model is highly recommended for models using administrative claims data. 9 Regression coefficients from the generalized linear model help to quantify the relationship between 12-month stroke-related costs and the selected patient characteristics (eg, when exponentiated using a base of e, the coefficient represents a percentage increase/decrease in costs compared to patients without the characteristic). Adjusted stroke-related hospitalization rates were estimated using a logistic regression controlling for the same covariates included in the generalized linear model.
Results
We identified 160 456 patients with stroke or TIA, 23 807 (14.8%) of whom had AF (Table 1) . Of the AF patients, 43.5% were on an oral-anticoagulant in the baseline period. There Table 2 . 
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Continued were differences in terms of demographic and clinical characteristics between the AF and non-AF groups. In the AF cohort, mean age was 77 years (AE11.6) compared to a mean age of 67 years (AE14.8) in the non-AF cohort (P<0.01) ( Table 1) . Prevalence of selected comorbidities was also higher in the AF cohort (P<0.01).
In the overall sample, 49.9% of patients had IS, 13.9% had HS, and 36.2% had TIA (12.2% identified with ED; 24.0% identified with hospitalization). Compared to the non-AF cohort, the AF cohort had higher rates of IS, intracerebral hemorrhage, and other intracranial hemorrhage and lower rates of TIA and subarachnoid hemorrhage (Table 1) .
Among IS and TIA patients, the AF cohort had longer index hospitalization LOS than the non-AF cohort (8.3 versus 7.9 for IS; 4.1 versus 3.4 for TIA), but the opposite was true for HS patients (10.7 versus 14.1 days). Among patients surviving the index event, hospitalization within 30 days of discharge was significantly more common among AF patients, regardless of index stroke type (OR=1.248 P<0.05 for IS; OR=1.424 P<0.05 for HS; OR=1.425 P<0.05 for TIA).
Unadjusted mean cost of index event was $20 933 (AE$37 413) for IS, $59 054 (AE$99 512) for HS, $8616 (AE10 812) for TIA with index hospitalization, and $3395 (AE3862) for TIA with index ED visit ( Table 2) . Adjusted mean incremental costs (index plus 12-month post-index) for AF patients were significantly higher than those for non-AF patients by: $4726, $7824, and $1890 for index IS, HS, TIA (identified by hospitalization), respectively, and $1700 for TIA (identified by ED) (all P<0.01). In the multivariate regression predicting stroke-related follow-up costs (index plus 12-month post-index), AF was associated with significant increases in total stroke-related costs among patients with IS (20%), HS (13%), and TIA (19%) (all P<0.01) ( Table 3 ).
Discussion
In this study, we estimate the direct cost of stroke-related medical care among patients with AF versus those without AF using a large payer database. After controlling for potential confounders, adjusted mean incremental costs (index plus 12-month post-index) for AF patients were significantly higher than those for non-AF patients, with results from a generalized linear model demonstrating the statistical significance of this relationship. This study is subject to the general limitations of basing case ascertainment on ICD-9-CM codes from billing data, including coding errors and potential underestimation of event occurrence. We only counted follow-up costs for medical care that listed stroke/TIA as a diagnosis; also, this likely underestimates the full costs experienced by patients, because some stroke-related services may be coded for specific complications rather than strictly stroke or TIA. However, our index hospitalization and post-index strokerelated cost findings are consistent with estimates reported from previous studies using various sources of data. 3, 10 While limited data exist on the relationship between AF and stroke-related costs from a US perspective, multiple published studies have attempted to evaluate this relationship with non-US data sources. For instance, a 2008 article published by Ghatnekar and colleagues evaluated the impact of AF on stroke-related inpatient costs over a 3-year follow-up period in Sweden. 11 Due to a higher observed mortality rate during the index stroke hospitalization, patients with AF had a shorter mean follow-up period than those without the disease, resulting in a non-significant difference in costs between the 2 cohorts over the full follow-up period. The effect of AF on stroke-related inpatient costs became statistically significant once only patients surviving the index event were included in the regression analysis (€818 higher, P<0.01), a criterion also employed in our study. An analysis of data from the Berlin Acute Stroke Study also established a significant relationship between the presence of AF and higher total direct costs within 1 year of an index stroke event (€2982 higher, P<0.001), with resource use and cost data obtained from a patient self-report survey. 12 In addition to providing data from a US perspective, our study adds to this body literature by providing estimates on stroke-related costs for all components of medical care (eg, inpatient, outpatient, rehabilitation) to third-party payers stratified by stroke type. Our findings provide current estimates of the cost of various stroke types, including ischemic stroke, hemorrhagic stroke, and TIA. These results demonstrate the high economic burden of stroke to payers, especially in persons with AF. Therefore, reducing the risk of AF-related stroke may be important from both a clinical and economic standpoint. Professional guidelines recommend oral anticoagulant therapy for the prevention of stroke in patients with AF. 13 Data from this analysis will be useful when evaluating the cost-effectiveness of clinical interventions designed to prevent stroke among those with AF, such as new developments in anticoagulant therapy.
